logo-loader
Advanced Oncotherapy PLC

Advanced Oncotherapy on track

“We have exciting plans for the future commercialisation of the LIGHT system once completely developed, and our discussions with potential partners around the world are ongoing,” said chief executive Nicolas Serandour

Harley Street sign
The company's base will be on Harley Street in London's West End

Advanced Oncotherapy PLC (LON:AVO), which is developing a breakthrough new proton therapy system for cancer sufferers, said it remains on course to treat its first patients in the second half of 2020.

Work on its base on London’s Harley Street is on schedule, while financially the group is well placed having raised £40mln this year, which has helped it eliminate financial pledges over the company's assets.

On Thursday investors were told the company’s LIGHT system had passed a major technological milestone with the unit generating proton beams energetic enough to treat superficial tumours.

Commercially AVO’s technology is gaining traction. It has inked a distribution agreement with Liquid Harmony for China and other parts of Asia, while discussions are ongoing for sites in the US, Europe, Asia and the Middle East.

Exciting commercial plans

“We have exciting plans for the future commercialisation of the LIGHT system once completely developed, and our discussions with potential partners around the world are ongoing,” said chief executive Nicolas Serandour.

LIGHT stands for Linac Image Guided Hadron Technology. The AVO kit is cheaper and smaller than the current units, which are almost prohibitively expensive.

It has the ability to propel protons at the speeds generated by much larger machines.

The proton accelerator used by Advanced Oncotherapy was licensed from CERN, the European Organisation for Nuclear Research, which is currently hunting the ‘God particle’.

Returning to the interim results, the financials showed the company recorded a loss of almost £11.5mln for the six months to June 30, which was expected given the heavy investment made during the period to develop both the proton beam system and the new London facility.

Cash and equivalents at the period-end were £3.32mln, though this figure excluded £6.41mln raised from investors and a £2.92mln tax credit, which occurred early in the second half.

Quick facts: Advanced Oncotherapy PLC

Price: £0.37

Market: LSE
Market Cap: £85.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Advanced Oncotherapy PLC named herein, including the promotion by the Company of Advanced Oncotherapy PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tertiary Minerals, Advanced Oncotherapy among Alan Green's 2018 stocks to watch

Brand Communications' Alan Green highlights his small cap stocks to watch in 2018. First on Alan's hit list is Tertiary Minerals (LON:TYM). Tertiary’s share price has been on a good run recently since it announced they'd signed an MoU with global commodities group Possehl to enter...

on 27/12/17

2 min read